IP Library Granted Patent US 7,892,744
Granted Patent B2
US 7,892,744 · App. 12/567,942 · Granted Feb 22, 2011

Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,892,744
App. No.
12/567,942
Granted
Feb 22, 2011
Kind
B2
Abstract

The invention relates to polynucleotide sequences comprising genetic variations of the PAR1 gene at positions 3090 and/or 3329. The occurrence of these variants in humans correlates with increased occurrence of particular cardiovascular disorders. The invention furthermore relates to methods for detecting said genetic variations for the purpose of patient diagnosis.

Claims (9)

1. An isolated polynucleotide consisting of nucleotide 3090 to nucleotide 3329 of SEQ ID NO: 4.

2. A method of determining a patient's relative risk of a cardiovascular disorder, comprising:

a. obtaining a nucleic acid sample from the patient; and

b. determining the presence in the nucleic acid sample of at least one single nucleotide polymorphism of the PAR1 gene, selected from the group of polymorphisms corresponding to a C for T substitution at position 3090 and a C for A substitution at position 3329 of SEQ ID NO: 1;

wherein the presence of the at least one polymorphism is diagnostic of a patient's relative risk of atrial fibrillation, acute coronary syndrome, cardiomyopathy or unstable angina.

3. The method of claim 2 , wherein the step of determining the presence of at least one single nucleotide polymorphism comprises amplification of a portion of the nucleic acid sample comprising position 3090 of SEQ ID NO: 1 by polymerase chain reaction.

4. The method of claim 2 , wherein the step of determining the presence of at least one single nucleotide polymorphism comprises amplification of a portion of the nucleic acid sample comprising position 3329 of SEQ ID NO: 1 by polymerase chain reaction.

5. The method of claim 2 , wherein the step of determining the presence of at least one single nucleotide polymorphism comprises sequencing of a portion of the nucleic acid sample comprising position 3090 of SEQ ID NO: 1.

6. The method of claim 2 , wherein the step of determining the presence of at least one single nucleotide polymorphism comprises sequencing of a portion of the nucleic acid sample comprising position 3329 of SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2010
From: KOZIAN, DETLEF; CZECH, JOERG; SIEGLER, KARL-ERNST; DELEUZE, JEAN-FRANCOIS; RICARD, SYLVAIN; MACE, SANDRINE
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 024605/0668 →
CHANGE OF NAME Recorded Jun 28, 2010
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 024605/0685 →